Innoventric
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Chaim Holzman St, Rehovot, Central Dis...Website
www.innoventric.comRevenue
$5.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Innoventric
Since its foundation, Innoventric has been committed to addressing the complexities of tricuspid regurgitation with the company's transcatheter TR solutions. As leaders in cross-caval technologies, the company is dedicated to the ongoing development of advanced devices to extend the reach of TR treatment. The company's approach is rigorously data-driven, with its roots grounded deep in clinical research. The company possess a robust patent portfolio in cross-caval technologies and are devoted to continuous improvement to enhance patient care for those with structural heart disease. The company's treatments are designed to benefit a broad spectrum of patients, with the aim of making high-quality care more accessible and improving health outcomes.Explore more
Innoventric Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Innoventric your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Innoventric had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if Innoventric has recently received funding, and reach out quickly before it becomes old news!
Check out if Innoventric is spiking on competitors!
Innoventric, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Innoventric launches new products
Congratulate Masked Content for being promoted to Masked Content at Innoventric
Earning: See what the market has to say on Innoventric recently announced quarterly report
Funding: Get notified immidiatlly once Innoventric has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Innoventric is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Innoventric is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Innoventric.
Innoventric financials insights
Gather financial insights about Innoventric, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$14M
2024
Series B
$28.5M
Innoventric Tech Stack
A closer look at the technologies used by Innoventric
See more technologies
Innoventric News & Media
Israeli Medical Device Startup, Innoventric Ltd., Wins the Prestigious Horizon Europe Grant and Secures US $14M in Series A Investment
NESS-ZIONA, Israel, Nov. 1, 2021 /PRNewswire/ -- Innoventric, a start-up company from Ness-Ziona, Israel, develops the unique Trillium™ technology for the treatment of Tricuspid Valve Regurgitation. The company was founded in 2017, and has rapidly progressed. Innoventric has performed...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Innoventric
Sign Up For FreeTo access detailed company insights
Since its foundation, Innoventric has been committed to addressing the complexities of tricuspid regurgitation with the company's transcatheter TR solutions. As leaders in cross-caval technologies, the company is dedicated to the ongoing development of advanced devices to extend the reach of TR treatment. The company's approach is rigorously data-d... Read More
